Breaking News
Get 40% Off 0
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks
Close

Chimerix Inc (CMRX)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Chimerix's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
0.900 +0.009    +1.00%
- Closed. Currency in USD ( Disclaimer )
After Hours
0.905
+0.005
+0.544%
- Real-time Data
Type:  Equity
Market:  United States
  • Volume: 225,996
  • Bid/Ask: 0.892 / 0.905
  • Day's Range: 0.882 - 0.909
Chimerix 0.900 +0.009 +1.00%

Chimerix Inc Company Profile

 
Get an in-depth profile of Chimerix Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

72

Equity Type

ORD

Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors. The company also develops ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for oncology indications; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2. It has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.

Contact Information

Address 2505 Meridian Parkway Suite 100
Durham, 27713
United States
Phone 919-806-1074
Fax 919-806-1146

Top Executives

Name Age Since Title
Douglas D. Richman - - Member of Scientific Advisory Board
Earl R. Kern - - Member of Scientific Advisory Board
C. Patrick Machado 60 2014 Independent Director
Martha J. Demski 71 2005 Lead Independent Director
Fred A. Middleton 75 2018 Independent Director
Michael A. Sherman 58 2019 Chairman
Michael Boeckh - - Member of Clinical Advisory Board
Robert James Meyer 65 2018 Independent Director
Michael T. Andriole 51 2019 CEO, President & Director
Pratik S. Multani 57 2020 Independent Director
Seth A. Rudnick 75 - Member of Scientific Advisory Board
Victoria M. Vakiener 60 2021 Independent Director
Raymund R. Razonable - - Member of Clinical Advisory Board
Lisa L. Decker 54 2023 Director
Marc D. Kozin 63 2024 Director
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

CMRX Comments

Write your thoughts about Chimerix Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Nov 03, 2022 5:37AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
good day today isn?t it?
Sadam Vang
Sadam Vang Aug 06, 2022 2:53PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
let's go
kiven Geldon
kiven Geldon Jun 29, 2022 10:52AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
women and kids getting it now. dynamics are different this time.
Ty
Ty Jun 29, 2022 10:52AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
This is just beginning mainstream attention in 1-3 months max
peter pan
peter pan Jun 29, 2022 8:57AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
what big moves? any news?
Ty
Ty Jun 28, 2022 11:43AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Big moves coming load up
Giuseppe Giannachi
Giuseppe Giannachi May 16, 2022 9:33AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
wow...
Justin Wayne
Justin Wayne Jan 08, 2021 12:39PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
looks weak
Giuseppe Giannachi
Giuseppe Giannachi Jan 08, 2021 12:02PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Anyone?
Manolis Karantinos
Manolis Karantinos Dec 30, 2015 9:41PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Anybody in here? The -81% was an opportunity to enter at ~7$
All In Capital Inc
All In Capital Inc Dec 30, 2015 9:41PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
everyone is on stocktwits for this
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email